Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Agenda
- Candidate gene approach
- GWAS hits - the progress
- Genome wide scans - case control approach
- Replicate in larger/second sample
- GWAS data presented as a “Manhattan Plot”
- Chromosome 9p21.3 CHD SNP
- Bigger GWAS leads to more loci - the CARDIoGRAM Study
- > 170 CHD GWAS loci
- Progress with GWAS lipid genes
- Study sample
- 50K Illumina cardio-metabolic chip
- Results: Manhattan plots for LDL-C - genic plots
- Percentage of variance explained (1)
- Percentage of variance explained (2)
- Explaining the variance in lipid traits
- Where is the hidden genetic effect?
- Limits of current GWAS
- Exome chips discovered many novel loci
- Negative relationship between frequency and effect size
- Genomic position of CHD variants
- GWAS hits - the problem!
- Carotid intima media thickness (cIMT)
- The IMPROVE study (1)
- 4 carotid segments for each carotid
- The IMPROVE study (2)
- Results from the IMPROVE study
- IMPROVE genetic study (1)
- IMPROVE genetic study (2)
- Map of novel IMT locus on chromosome 16
- Moving from GWAS hits to functional variants
- Stage 2 - bioinformatics: hypothesis
- Stage 2 - bioinformatics
- Allele-specific expression: GTEx (1)
- Allele-specific expression: GTEx (2)
- Very strong LD at the locus
- Which SNPs are in predicted regulatory regions?
- Stage 2 - shortlist of SNPs
- Stage 3 - Electrophoretic Mobility Shift Assay (EMSA)
- EMSA with all shortlist SNPs
- Multiplex competitor EMSA
- Stage 2 -luciferase reporter assay
- Luciferase reporter assay
- Luciferase reporter assay: results
- Mechanism of SNP effect
- Stage 4: why might BCAR1 be involved in cIMT and CVD?
- Protein structure of BCAR1/p130Cas
- Conclusion
Topics Covered
- Candidate gene approach
- GWAS hits
- The Cardiogram Study
- Exome chips: many novel loci
- Genomic position of CHD variants
- Genetic determinants of cIMT
- The IMPROVE study
Links
Series:
- Genetics of Cardiovascular Disease
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
External Links
Talk Citation
Humphries, S. (2024, January 31). Moving from GWAS hits to functional variants [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 20, 2024, from https://doi.org/10.69645/CZIG2261.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Humphries is the Medical Director of StoreGene a UCL spin out company that offers DNA testing for Cardiovascular Disease risk including testing for FH. Professor Humphries is a consultant for Verve Therapeutics, a US based company that is developing gene-editing agents to treat individuals with hypercholesterolaemia, including those with FH.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Steve Humphries.
I'm the emeritus professor of
Cardiovascular Genetics at
University College in London.
I'm going to be
talking today about
moving from Genome Wide
Association Study Hits,
that is GWAS Hits to identifying
the functional variants
that underlie those hits.
0:21
First off, we'll talk about
GWAS hits for
cardiovascular disease,
that is CVD, and then focus
on GWAS hits in lipid genes.
Now, not all problems
are solved by
using the GWAS technology.
I'll illustrate this
using a study where we
examine the phenotype of
carotid intimal
medial thickness,
that's CIMT and a big study
I've been involved
in called iMprOVE.
I'll demonstrate the use
of bioinformatic tools and
present the results of
the molecular approaches
that we've used in this work.
0:54
Now when we started trying to
find genes involved in
cardiovascular disease,
we used what we call a
candidate gene approach.
We identified a gene that has
the potential to be
involved in CHD,
coronary heart disease,
or cardiovascular disease,
because we knew what
the gene coded for,
and we knew that that
protein was important in
some of the pathophysiology
of heart disease;
for example, in determining
lipid levels in the blood.
We looked at the association of
a single nucleotide
polymorphism, that is a SNP,
with an intermediate
trait, for example,
with cholesterol levels
in the blood or with
cardiovascular disease
in a prospective study.
This was usually a
frequency comparison
in a large group of cases with
cardiovascular disease
versus a large group
of controls who didn't
have the disease.
This is how we were doing
these studies to try to find
genes involved in CVD
before June 2007,
which was when, of course,
we had the benefit of
the whole genome project and
we knew now the sequence of
the entire human genome.
Here's the timeline
and what happened in
June 2007 was because of
this advancing technology.
Instead of doing a single SNP
in a case-control design,
we were able to use
genome-wide association scans.
We were able to use the
power of the whole genome.